Dermatology
News
FDA announces approval of fifth adalimumab biosimilar, Abrilada
Pfizer said that current plans are to launch the drug in the United States in 2023.
News
AAD-NPF Pediatric psoriasis guideline advises on physical and mental care
Topics in this guideline for pediatric psoriasis include systemic and topical treatments, management of comorbidities, and quality of life.
Conference Coverage
Melanoma incidence continues to increase, yet mortality stabilizing
LAS VEGAS –Targeted screening efforts that stratify by risk factors and by age “makes screening more efficient and more cost effective.”
FDA/CDC
FDA approves afamelanotide for treatment of rare condition with light-induced pain
This is the first treatment approved to help patients with erythropoietic protoporphyria increase their exposure to light.
News
FDA approves Taltz for treatment of ankylosing spondylitis
The approval is based on results from a pair of randomized, double-blind, placebo-controlled, phase 3 studies involving 657 adult patients with...
Clinical Review
Translating the 2019 AAD-NPF Guidelines of Care for the Management of Psoriasis With Biologics to Clinical Practice
In February 2019, the American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) released a novel set of guidelines...
Conference Coverage
Too many blood cultures ordered for pediatric SSTIs
SEATTLE – Culture draws were associated with a 20% increase in hospital length of stay.
Conference Coverage
Psychology consult for children’s skin issues can boost adherence, wellness
Conference Coverage
Online ped-derm searches: What are folks looking for?
AUSTIN – Survey respondents self-diagnosed a number of dermatologic conditions based on their time spent online.
Conference Coverage
Cellulitis ranks as top reason for skin-related pediatric inpatient admissions
AUSTIN, TX – The median length of stay for patients was 2 days, with a median cost of $6,289.50 for each case.